PCH
ELVN icon

Polar Capital Holdings’s Enliven Therapeutics ELVN Stock Holding History

Polar Capital Holdings’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326M Buy
6,430,636
+1,364,703
+27% +$57.9M 0.77% 31
2026
Q1 		$199M Buy
5,065,933
+1,552,253
+44% +$43M 0.71% 39
2025
Q4 		$54.1M Buy
3,513,680
+418,673
+14% +$8.34M 0.21% 93
2025
Q3 		$63.4M Buy
3,095,007
+44,713
+1% +$901K 0.3% 83
2025
Q2 		$61.2M Buy
3,050,294
+685,000
+29% +$13M 0.32% 78
2025
Q1 		$46.5M Sell
2,365,294
-24,374
-1% -$525K 0.28% 99
2024
Q4 		$53.8M Buy
2,389,668
+1,739,668
+268% +$45.1M 0.3% 88
2024
Q3 		$16.6M Hold
650,000
– – 0.08% 160
2024
Q2 		$15.2M Buy
+650,000
New +$13.7M 0.09% 159

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Polar Capital Holdings's ELVN Position: Q2 2026 in Review

Polar Capital Holdings increased its Enliven Therapeutics (ELVN) stake by 27% in Q2 2026, buying an estimated $57.9M and bringing the position to 6,430,636 shares worth $326M. The position accounts for 0.77% of the portfolio, ranked #31.

Polar Capital Holdings first reported a position in ELVN in Q2 2024 and has held it in 9 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Polar Capital Holdings held 6,430,636 shares of Enliven Therapeutics worth $326M as of Q2 2026.
  • Polar Capital Holdings bought 1,364,703 Enliven Therapeutics shares in Q2 2026, an estimated $57.9M.
  • Enliven Therapeutics made up 0.77% of Polar Capital Holdings's portfolio in Q2 2026, its #31 holding.
  • Polar Capital Holdings first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.